GLP-1 weight loss 'updates' on TikTok: what the data says

What's this video probably claiming?

Based on the caption 'I did it' paired with Mounjaro and Wegovy hashtags, this is almost certainly a personal weight loss milestone video. The creator is likely sharing a before/after reveal, a goal weight reached, or a significant number of pounds lost after a course of GLP-1 receptor agonist therapy. These 'update' videos follow a reliable TikTok formula: emotional reveal, scale footage, clothing comparison, or side-by-side photos. What rarely gets mentioned in the 60-second celebration is the clinical scaffolding that made the result possible, including supervised titration, dietary changes, and the very real question of what happens when the medication stops. The enthusiasm is genuine and the results may well be real. But 37,000 viewers are watching a personal story, not a clinical summary, and those two things carry very different levels of generalizability.

What does the science actually show?

The clinical data on these drugs is genuinely impressive, which is part of why these videos get made. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), tirzepatide (Mounjaro) at the 15mg dose produced mean weight loss of 20.9% of body weight over 72 weeks in adults with obesity but without diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg (Wegovy) produced 14.9% mean weight loss over 68 weeks. These are not marginal numbers. They are the largest weight reductions ever recorded in pharmacological trials for obesity. But 'mean' matters here. A meaningful subset of participants lost considerably less, and roughly 10-15% of participants in GLP-1 trials are classified as low responders. The headline number is not a guarantee.

Where does the social media noise diverge from clinical reality?

The divergence is not usually in the results claimed. It is in what gets left out. First, the regain data. The STEP 4 withdrawal trial (Rubino et al., 2021, JAMA) showed that participants who stopped semaglutide regained two-thirds of their prior weight loss within one year. Tirzepatide shows a similar pattern in the SURMOUNT-4 data (Aronne et al., 2024, JAMA). These are not side effects, they are the expected pharmacology of a drug that suppresses appetite while you take it. Second, side effects rarely appear in celebratory videos. Nausea affects roughly 40-44% of participants in GLP-1 trials, vomiting affects 20-24%, and the rate of serious gastrointestinal adverse events requiring discontinuation is not trivial. Third, these videos often blur the line between tirzepatide and semaglutide, treating them as interchangeable. They are not the same mechanism, the same trial profile, or the same regulatory approval pathway.

What should you actually know?

If you are watching 'update' videos and considering GLP-1 therapy, the results you see on TikTok are not fabricated, but they are selected. People who have dramatic responses post videos. People who had modest responses, significant side effects, or who regained weight after stopping generally do not. That is not dishonesty, it is human nature, but it creates a systematically skewed picture for the 37,000 people watching. The clinical infrastructure behind these results matters: titration schedules, dietary protein targets, resistance training to preserve lean mass (Biermann et al., 2023, Obesity), and a clear plan for what comes after the medication phase. FormBlends works with licensed clinicians precisely because these decisions require individual medical context, not a TikTok comment thread. A personal milestone is worth celebrating. It is just not a treatment protocol.